Patents by Inventor Geoffrey F. Lee
Geoffrey F. Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240170714Abstract: A energy storage device for cycling between a charged state and a discharged state, the energy storage device including an enclosure, an electrode assembly and a non-aqueous liquid electrolyte within the enclosure, and a constraint that maintains a pressure on the electrode assembly as the energy storage device is cycled between the charged and the discharged states.Type: ApplicationFiled: December 6, 2023Publication date: May 23, 2024Inventors: Robert S. Busacca, Ashok Lahiri, Murali S. Ramasubramanian, Bruno A. Valdes, Gardner Cameron Dales, Christopher J. Spindt, Geoffrey Matthew Ho, Harrold J. Rust, III, James D. Wilcox, John F. Varni, Kim Han Lee, Nirav S. Shah, Richard J. Contreras, Lynn Van Erden, Ken S. Matsubayashi, Jeremie J. Dalton
-
Patent number: 11961952Abstract: A secondary battery is provided for cycling between a charged and a discharged state, the secondary battery including a battery enclosure, an electrode assembly, carrier ions, a non-aqueous liquid electrolyte within the battery enclosure, and a set of electrode constraints. The set of electrode constraints includes a primary constraint system having first and second primary growth constraints and at least one primary connecting member, the first and second primary growth constraints separated from each other in the longitudinal direction, wherein the primary constraint array restrains growth of the electrode assembly in the longitudinal direction such that any increase in the Feret diameter of the electrode assembly in the longitudinal direction over 20 consecutive cycles of the secondary battery is less than 20%.Type: GrantFiled: September 6, 2022Date of Patent: April 16, 2024Assignee: Enovix CorporationInventors: Robert S. Busacca, Ashok Lahiri, Murali Ramasubramanian, Bruno A. Valdes, Gardner Cameron Dales, Christopher J. Spindt, Geoffrey Matthew Ho, Harrold J. Rust, III, James D. Wilcox, John F. Varni, Kim Han Lee, Nirav S. Shah, Richard J. Contreras, Lynn Van Erden, Vladimir Dioumaev
-
Publication number: 20200223913Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.Type: ApplicationFiled: January 10, 2020Publication date: July 16, 2020Inventors: Daniel S. ALLISON, Steven D. DAVIN, Hoa Binh DO, Leon F. GARCIA-MARTINEZ, Geoffrey F. LEE, Ethan W. OJALA, Mark YOUNG, John A. LATHAM
-
Patent number: 10533045Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.Type: GrantFiled: October 21, 2016Date of Patent: January 14, 2020Assignee: ALDER BIOPHARMACEUTICALS, INC.Inventors: Daniel S. Allison, Steven D. Davin, Hoa Binh Do, Leon F. Garcia-Martinez, Geoffrey F. Lee, Ethan W. Ojala, Mark Young, John A. Latham
-
Publication number: 20180142038Abstract: A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated proteins, such as proteins produced by fungi. Assays using these anti-glycoprotein antibodies for monitoring the presence of glycoproteins in a sample are provided. Such methods can be used to monitor methods for production and/or purification of desired polypeptides, which may be used to modify process parameters to modify (e.g., decrease or increase) the amount of glycosylated polypeptide produced and/or present in the purified product. Also provided are methods of using the subject antibodies for detecting the level of expression and secretion of a polypeptide, and methods of using the subject antibodies to purify or deplete a glycoprotein from a sample. In exemplary embodiments, the desired polypeptide may be a multi-subunit protein, such as an antibody, which may be produced in a yeast, such as Pichia pastoris.Type: ApplicationFiled: January 15, 2016Publication date: May 24, 2018Applicant: ALDER BIOPHARMACEUTICALS, INC. a/b/a ALDERBIO HOLDINGS LLCInventors: Pamela BROWN, Geoffrey F. LEE, Benjamin DUTZAR, Jenny A. MULLIGAN, Daniel S. ALLISON, Ethan W. OJALA, Amarjeet SINGH
-
Publication number: 20170137500Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.Type: ApplicationFiled: October 21, 2016Publication date: May 18, 2017Inventors: Daniel S. ALLISON, Steven D. Davin, Hoa Binh Do, Leon F. Garcia-Martinez, Geoffrey F. Lee, Ethan W. Ojala, Mark Young, John A. Latham
-
Patent number: 9518082Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.Type: GrantFiled: March 17, 2014Date of Patent: December 13, 2016Assignee: ALDERBIO HOLDINGS LLCInventors: Daniel S. Allison, Steven D. Davin, Hoa Binh Do, Leon F. Garcia-Martinez, Geoffrey F. Lee, Ethan W. Ojala, Mark Young, John A. Latham
-
Publication number: 20140288272Abstract: Processes for producing and purifying recombinant proteins are disclosed. In particular, the present disclosure provides processes of producing and purifying multi-subunit proteins expressed in yeast or filamentous fungal cells. The production and/or purification of such proteins are monitored for impurities, preferably using lectin binding assays, such that one or more process parameters may be adjusted to maximize the amount of desired recombinant protein and minimize the amount of glycosylated impurities. The processes can also be monitored for other undesired product-associated impurities, such as aggregates and nucleic acids. In exemplary embodiments, the recombinant proteins are multi-subunit proteins, such as antibodies, the host cell is a yeast, such as Pichia pastoris, and the glycosylated impurity is a glycovariant of the desired recombinant polypeptide, such as an N-linked and/or O-linked glycovariant.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Applicant: ALDERBIO HOLDINGS LLCInventors: Daniel S. ALLISON, Steven D. DAVIN, Hoa Binh DO, Leon F. GARCIA-MARTINEZ, Geoffrey F. LEE, Ethan W. OJALA, Mark YOUNG, John A. LATHAM
-
Patent number: 8759027Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: GrantFiled: December 19, 2012Date of Patent: June 24, 2014Assignee: ZymoGenetics, Inc.Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
-
Publication number: 20100003722Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: ApplicationFiled: August 7, 2009Publication date: January 7, 2010Applicant: ZymoGenetics, LLCInventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
-
Publication number: 20080096252Abstract: The expression vectors and methods using an E. Coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.Type: ApplicationFiled: October 4, 2006Publication date: April 24, 2008Inventors: Bruce L. Zamost, Geoffrey F. Lee, Robert M. Dedinsky
-
Patent number: 7211560Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: December 29, 2003Date of Patent: May 1, 2007Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Publication number: 20040259769Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: ApplicationFiled: December 29, 2003Publication date: December 23, 2004Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Publication number: 20040006217Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: ApplicationFiled: April 30, 2003Publication date: January 8, 2004Applicant: Genentech, Inc.Inventors: Robert F. Kelley, Geoffrey F. Lee
-
Patent number: 6670323Abstract: The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.Type: GrantFiled: November 10, 2000Date of Patent: December 30, 2003Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Douglas L. Looker, Izydor Z. Apostol, Eric A. Brucker, Michael P. Doyle, David L. Foster, Christopher B. Glascock, James C. Hartman, Geoffrey F. Lee, Douglas D. Lemon, Edwin G. Moore, Jane P. Richards, Michael R. Schick, Stephen P. Trimble, David Pereira, Ton-That Hai, Kenneth E. Burhop
-
Patent number: 6596847Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: July 14, 1999Date of Patent: July 22, 2003Assignee: Genentech, Inc.Inventors: Robert F. Kelley, Geoffrey F. Lee
-
Publication number: 20020142373Abstract: The invention provides amino acid sequence variants of tissue factor protein. The tissue factor protein variants have a greater affinity for Factor VII/VIIa than wild-type counterparts. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: ApplicationFiled: July 14, 1999Publication date: October 3, 2002Applicant: GENENTECH, INC.Inventors: ROBERT F. KELLEY, GEOFFREY F. LEE
-
Patent number: 5874407Abstract: The invention provides compositions having a Factor VIIa active site inhibitor domain and a tissue factor domain for the inhibition of FVIIa. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: September 17, 1997Date of Patent: February 23, 1999Assignee: Genentech, Inc.Inventors: Robert F. Kelley, Robert A. Lazarus, Geoffrey F. Lee
-
Patent number: 5736364Abstract: The invention provides compositions having a Factor VIIa active site inhibitor domain and a tissue factor domain for the inhibition of FVIIa. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: December 4, 1995Date of Patent: April 7, 1998Assignee: Genentech, Inc.Inventors: Robert F. Kelley, Robert A. Lazarus, Geoffrey F. Lee